Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

SYST. pharma Wk2 > Antihyperlipidemics > Flashcards

Antihyperlipidemics Flashcards

1
Q

ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA
+ tx

A

•Increased risk of atherosclerosis is
associated with hypercholesterolemia
● Increases risk of cardiovascular (CV) and
cerebrovascular diseases

-Statins:
• lower plasma cholesterol
• Reducing CV events by 25–50% and prolonging life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ATHEROMA + what do risk factors cause

A

Focal disease of the intima of large and medium-sized arteries

Many of the risk factors cause endothelial dysfuntion

Healthy endothelium produces nitric oxide (NO) and other mediators that protect against atheroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ATHEROGENESIS: what happens

A

-Endothelial dysfunction
-Altered NO biosynthesis
-Injury of endothelium leads to expression of adhesion molecules
-Monocyte attachment and migration into the intima -Low-density lipoprotein (LDL) cholesterol oxidised(oxLDL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ATHEROGENESIS (oxLDL)

A

•oxLDL is taken up by macrophages (foam cells) •oxLDL activates macrophages
-Releases proinflammatory cytokines
•Foam cells and T lymphocytes form fatty streaks •Proliferation of smooth muscle
-Deposition of connective tissue components
-Atheromatous plaque
•Plaque can rupture
•Forming a substrate for thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Exogenous pathway (from diet)

A

•Cholesterol and triglycerides absorbed from ileum •Transported as chylomicrons to muscle and adipose tissue
•Triglycerides are hydrolysed by lipoprotein lipase
-Tissues take up the resulting free fatty acids and glycerol
•Chylomicron remnants pass to the liver
•Undergo endocytosis via receptors on hepatocytes •Cholesterol liberated in hepatocytes
Stored
Oxidised to bile acids
Secreted unaltered in bile
Enters into the endogenous pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Endogenous pathway

A

•Cholesterol and newly synthesised triglycerides are transported from the liver as VLDL to muscle and adipose tissue
-Triglycerides are hydrolysed to fatty acids and glycerol; these enter the tissues
• Lipoprotein particles become LDL particles
-Key in atherogenesis
•Cells take up LDL by endocytosis via LDL receptors that recognise apoB-100
•Reverse cholesterol transport
Cholesterol can return to plasma from the tissues in HDL particles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Endo pathway cholesterol, lipoprotein

A

·Cholesterol esterified with long-chain fatty acids in HDL particles
·Resulting cholesteryl esters are transferred to VLDL or LDL particles by a transfer protein present in the plasma cholesteryl ester transfer protein (CETP)

·Lipoprotein(a),Lp(a), LDL species associated with atherosclerosis
-Localised in atherosclerotic lesions
/-May promote thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

PREVENTION OF ATHEROMATOUS Dx
What tx prevents this

A

•Treatment of hypertension and, to a lesser extent, diabetes mellitus reduces incidence of symptomatic atheromatous disease
•Antithrombotic drugs reduce arterial thrombosis
•Reducing LDL is also effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Main agents used clinically for lipid-lowering drugs

A

•Statins
•Fibrates
•Inhibitors of cholesterol absorption
•Nicotinic acid or its derivatives
•Other novel therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are STATINS

A

They are HMG-CoA Reductase Inhibitors.
The rate-limiting enzyme in cholesterol synthesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

STATINS examples

A

•Examples: simvastatin, lovastatin, pravastatin •Atorvastatin and rosuvastatin: long-lasting inhibitors
High-intensity statins at high doses: may reduce LDL by more than 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

STATINS MoA

A

•Decreased hepatic cholesterol synthesis
•Upregulates LDL receptor synthesis
-Increasing LDL clearance from plasma into liver cells
•Main biochemical effect of statins is therefore to reduce plasma LDL
•Some reduction in plasma triglyceride and increase in HDL

•Positive results on morbidity and mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ADVERSE EFFECTS of statins

A

•Statins are well tolerated

Mild unwanted effects:
•Muscle pain (myalgia)
•Gastrointestinal disturbance
•Hepatotoxicity (raised LFTs)
•Insomnia
•Rash
More serious adverse effects are rare
•Severe myositis (rhabdomyolysis)
•Angio-oedema
-Contraindicated in pregnancy

Drug interactions:
• w/ Gemfibrozil: increase risk of rhabdomyolysis
• w/ CYP450 inhibitors: increase toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CLINICAL USES of statins (revision)

A
  1. Secondary prevention of MI+ stroke who have symptomatic atherosclerotic dx. (Angina, transient ischaemic attacks)
  2. Primary prevention of arterial dx in pts who are at high risk b/c of elevated serum cholesterol conc., especially w/ other risk factors (diabetes)
    3,. Atorvastatin lowers cholesterol. In pts w/ homozygous Familial hypercholesterolaemia
  3. In severe drug resistant dyslipidaemia, ezetimibe is combined w: statin tx
  4. CI in pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Fibrates examples

A

Bezafibrate, ciprofibrate, gemfibrozil, fenofibrate, clofibrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What do Fibrates do

A

Markedly reduce circulating VLDL and triglycerides
Modest (approximately 10%) reduction in LDL
Approximately 10% increase in HDL

(Statins on the other hand are good at reducing LDL levels)
(Fibrates: good at reducing VLDL + triglycerides)

17
Q

Fibrates MoA

A

•Agonists at PPARα nuclear receptors
•Increase transcription of the genes for lipoprotein
lipase, apoA1 and apoA5
•They increase hepatic LDL uptake

Also:
•Reduce plasma C-reactive protein and fibrinogen
•Improve glucose tolerance
•Inhibit vascular smooth muscle inflammation

18
Q

Fibrates Adverse Effects

A

•Rhabdomyolysis is unusual but can be severe
-Occurs particularly in: •Renal impairment •Alcoholics
•Combined use of fibrates with statins is generally
inadvisable (sometimes undertaken by specialists)
•GI symptoms, pruritus and rash are more common than with statins
•Clofibrate (and other fibrates to a lesser extent) predispose to gallstones
-Clofibrate use is limited to patients who have had a cholecystectomy (i.e. removal of the gall bladder)

19
Q

DRUGS THAT INHIBIT CHOLESTEROL ABSORPTION
1. Bile acid-binding resins
Examples

A

Colestyramine, colestipol, colesevelam

20
Q

Bile acid-binding resins MoA

A

•Sequester bile acids in the intestine
• Prevent their reabsorption and enterohepatic recirculation
• Excretion in feces
•Decreased absorption of cholesterol
• Increased metabolism of endogenous cholesterol into bile acids in the liver
•Increased LDL receptor expression on hepatocytes

Evidence on survival is lacking, although effective at
reducing cholesterol levels

21
Q

Bile acid-binding resins
(HDL,LDL, triglycerides)

A

•HDL is unchanged, triglycerides are increased (CI in
hypertriglycemia)
•Increased clearance of LDL from the blood and a
reduced concentration of LDL in plasma
•Interfere with absorption of fat-soluble vitamins, thiazide diuretics, digoxin and warfarin

22
Q

Bile acid-binding resins

Adverse Effects:

A

May cause unacceptable constipation and bloating

23
Q

Bile acid-binding resins
Clinical uses

A

Additional treatment in patients with severe disease (e.g. FH)- Not commonly used

Bile salt-associated symptoms of pruritus (itch) and diarrhea

24
Q

DRUGS THAT INHIBIT CHOLESTEROL ABSORPTION
2. Ezetimibe
MoA

A

•Inhibits absorption of cholesterol (and of plant stanols) from the duodenum
-Blockade of a transport protein (NPC1L1) •Decreased LDL: stimulates LDL receptor synthesis •No effect on the absorption of fat-soluble vitamins, triglycerides or bile acids
•Results on CV outcomes in primary prevention lacking

25
Q
  1. Ezetimibe PK/PD
A

Generally well-tolerated
May cause diarrhea, abdominal pain, headache
Rash and angio-oedema have been reported

26
Q

Clinical use of drugs that reduce cholesterol absorption: ezetimibe/ bile-acid binding resins

A

•adjunct to statin when response isn’t enough (ezetimibe)
• for HYPERCHOLESTEROLAEMIA when statin is CI
• uses unrelated to atherosclerosis:
-priorities in pts w/ partial biliary obstrxn (bile acid-binding resin)
- bile acid diarrhoea , Causes by diabetic neuropathy (bile acid-binding resin)

27
Q

NICOTINIC ACID
MoA

A

● Converted to nicotinamide
• Inhibits hepatic VLDL secretion
•Consequent reductions in circulating triglyceride and LDL including Lp(a), and an increase in HDL

The mechanism is poorly understood
Effect on inhibition of lipolysis via HM74A receptor present in adipocyte membranes?

28
Q

NICOTINIC ACID
AE

A

•Flushing (vasodilation)
Associated with production of PGD2 + Reduced by aspirin
•Palpitations
•Gastrointestinal disturbance
•High doses:
-Disturbed liver function (hepatotoxic)
-Impaired glucose tolerance
-Gout precipitation

29
Q

Nicotinic Acid - clinical uses

A

Clinical uses:
•As adjunct to a statin and diet in dyslipidaemia, especially when associated with low HDL and raised triglycerides
•When a statin is contraindicated
•Contraindicated in peptic ulcers

30
Q

NOVEL THERAPIES

A
  1. Evolocumab, Alirocumab (PCSK9 Inhibitors)
  2. Mipomersen
  3. Lomitapide
31
Q
  1. Evolocumab, Alirocumab (PCSK9 Inhibitors)
    Clinical indications
A

●Recently-approved monoclonal antibodies for
Primary hypercholesterolaemia, mixed dyslipidaemia, adjunct to diet
•In combination with statin or statin with other lipid lowering therapies when unable to reach LDL-C goals
•Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin CI exists

32
Q
  1. Evolocumab, Alirocumab (PCSK9 Inhibitors) MoA
A

: ● Inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a hepatic protease
-PCSK9 promotes degradation of LDL receptor in hepatocytes by targeting it for lysosomal degradation

33
Q

‘1. Evolocumab, Alirocumab (PCSK9 Inhibitors
. ADVERSE EFFECTS

A

: ● Nasopharyngitis ● Upper respiratory tract infections ● Injection-site reactions ● Myalgia ● Cognitive effects

34
Q
  1. Mipomersen
    MoA
A

-,Adjunct treatment for FH
-Antisense oligonucleotide for coding region of apoB-100 mRNA

Inhibits its synthesis and apoB-100-containing lipoprotein synthesis

35
Q
  1. Mipomersen

AE+ pk

A

-,SC treatments once weekly-resistant to degradation
- liver accumulation ( intended axn site)

AE
- hepatotoxicity

36
Q

‘3. Lomitapide
Clinical use

A

-Licensed as adjunct treatment for FH

-Oral formulation

•Inhibitor of microsomal triglyceride transfer protein (MTP)
-Central in the assembly and release of apoB-
containing lipoproteins into circulation

● Plasma lipid levels decrease

SYST. pharma Wk2 (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions